Merus Announces 2019 Annual General Meeting of Shareholders
All relevant documents and information for the meeting, including the notice and agenda, are available in the 'Investor Relations' section of Merus’ website (www.merus.nl) under “Financial Information”.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information on the company and programs, please visit Merus’ website, www.merus.nl.
Investor and Media Inquiries:
Investor Relations and Corporate Communications
Source: Merus N.V.